UniQure's Huntington's therapy fails to significantly slow disease progression in trial
29/09/2026 12:35
UniQure's Huntington's therapy fails to significantly slow disease progression in trial Sept 29 (Reuters) - UniQure UQ1.F, QURE.O said on Tuesday its Huntington's treatment showed 44% slowing of disease progression, but did not reach statistical significance in an ongoing early-to-mid-stage trial.
U.S.-listed shares of the Dutch gene therapy developer fell 63% in premarket trading.
(Reporting by Christy Santhosh in Bengaluru; Editing by Diti Pujara and Sahal Muhammed)
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal